Sawai Group Holdings Co., Ltd.

OTCPK:SWGH.F Stock Report

Market Cap: US$1.8b

Sawai Group Holdings Valuation

Is SWGH.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SWGH.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SWGH.F ($40.2) is trading below our estimate of fair value ($72.12)

Significantly Below Fair Value: SWGH.F is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SWGH.F?

Key metric: As SWGH.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SWGH.F. This is calculated by dividing SWGH.F's market cap by their current earnings.
What is SWGH.F's PE Ratio?
PE Ratio14.4x
EarningsJP¥17.76b
Market CapJP¥256.47b

Price to Earnings Ratio vs Peers

How does SWGH.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SWGH.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.1x
SUPN Supernus Pharmaceuticals
34.2x36.2%US$2.0b
NDOI Endo
0.5xn/aUS$1.8b
INVA Innoviva
18.5xn/aUS$1.2b
LGND Ligand Pharmaceuticals
51.2x35.5%US$2.3b
SWGH.F Sawai Group Holdings
14.4x1.2%US$256.5b

Price-To-Earnings vs Peers: SWGH.F is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (17x).


Price to Earnings Ratio vs Industry

How does SWGH.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.5xn/aUS$1.76b
KPRX Kiora Pharmaceuticals
1.9x-40.4%US$10.71m
EDXC Endexx
0.9xn/aUS$5.88m
CNNC Cannonau
0.7xn/aUS$241.82k
SWGH.F 14.4xIndustry Avg. 19.8xNo. of Companies8PE01224364860+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SWGH.F is good value based on its Price-To-Earnings Ratio (14.4x) compared to the US Pharmaceuticals industry average (18.9x).


Price to Earnings Ratio vs Fair Ratio

What is SWGH.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SWGH.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SWGH.F's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies